Brief: Xintela, EQGen Biomedical Sign Collaboration And License Deal
25/04/2025 06:26
April 25 (Reuters) - Xintela AB XINT.ST: SAID ON THURSDAY XINTELA, EQGEN BIOMEDICAL SIGN COLLABORATION AND LICENSE DEAL FOR VETERINARIAN STEM CELL PRODUCTS XINTELA TO GET LICENSE FEE OF $1 MILLION AND $3 MILLION WORTH OF SHARES IN EQGEN XINTELA ALSO GETS VARIABLE ROYALTIES UP TO LOW DOUBLE DIGITS UPON SIGNING CO GETS $0.4 MILLION AS DEPOSIT FOR DEVELOPMENT OF GMP MANUFACTURING PROCESS FOR EQSTEM Source text for Workspace: ID:nMFN7nh19K Further company coverage: XINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects